Percutaneous hepatic ablation: What needs to be known in 2014
Percutaneous hepatic ablation: What needs to be known in 2014
复制标题
DOI：
10.1016/j.diii.2014.04.002
复制
发表时间：
2014-07-01
影响因子：
5.5
通讯作者：
Seror, O.
中科院分区：
文献类型：
--
作者：
Seror, O.
肝肿瘤的经皮治疗最初只适用于那些被认为不能手术且肿瘤体积和数量都很小的患者。由于技术和技术范围的扩大，这些治疗已逐渐被纳入越来越复杂的治疗策略，用于越来越广泛的患者群体。这些技术目前仍以单极射频消融为主，正面临着来自第二代微波的激烈竞争，这些技术的位置由每个中心在技术方面的知识和技能决定。这篇综述描述了可能的适应症，经皮消融取决于临床表现和技术和技术的选择。(C) 2014版法国放射学。Elsevier Masson SAS出版。版权所有。
Percutaneous treatments for liver tumors were initially reserved for patients deemed to be inoperable and whose tumors were small in both size and number. As a result of the widening range of both techniques and technologies these treatments have gradually become incorporated into increasingly complex treatment strategies for increasingly broad patient groups. The place reserved for these techniques, which are still dominated by monopolar radiofrequency ablation, which is now facing strong competition from second-generation microwaves, is governed by each center's knowledge and skills in the techniques. This review describes the possible indications for percutaneous ablation depending on clinical findings and the technical and technological choices made. (C) 2014 Editions francaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.